founded the topical area of pharmacokinetics. At age 34, Ken became the youngest person ever to hold an endowed chair at Cornell University—the Walter R. Read Professorship of Chemical Engineering. There he also was director of the School of Chemical Engineering (1970–1975). In 1976, Ken joined the University of Delaware as the Unidel Professor of Biomedical and Chemical Engineering. He remained at Delaware until, owing to health issues, he retired in 1997. He served as department chairman of chemical engineering (1978–1982) and as acting director of the Center for Catalytic Science and Technology (1983–1984).
Ken’s primary research interests were in the areas of chemical reaction engineering and applications to pharmacology and toxicology, resulting in more than 100 journal articles and two textbooks. His scholarly productivity was recognized with many awards, including the IIT Distinguished Alumni Award (1996) and several American Institute of Chemical Engineers (AIChE) awards: fellow (1987), Professional Progress (1976), Institute Lecture (1982), and Wilhelm Award (1987). He received the Ebert Prize from the Academy of Pharmaceutical Sciences (1972), became a fellow of the American Association for the Advancement of Science (AAAS; 1980), and was elected to the National Academy of Engineering (1988). Ken was also active in professional service for the AIChE: he was elected director (1972–1974), selected as program committee chairman (1978), and was session chairman for many sessions. For the American Chemical Society he was on the Awards Committee and the editorial board of the Industrial & Engineering Chemistry Annual Research Review and was an associate editor of the Advances in Chemistry series. He also was associate editor of Advances in Chemical Engineering (Elsevier), volumes 12 (1982) through 23 (1996). He was chairman of the First and cochairman of the Ninth International Symposium on Reactor Engineering. He also served as chairman of the Council for Chemical Research (1985).
Ken’s skills in mathematical model building led to significant and enduring consulting collaborations, particularly with Bob Dedrick at NIH and with many individuals at Exxon. His